Literature DB >> 25393798

Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib.

Gouji Toyokawa1, Fumihiko Hirai, Eiko Inamasu, Tsukihisa Yoshida, Kaname Nosaki, Tomoyoshi Takenaka, Masafumi Yamaguchi, Takashi Seto, Mitsuhiro Takenoyama, Yukito Ichinose.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25393798     DOI： 10.1097/JTO.0000000000000358

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  23 in total

1.  Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.

Authors:  Justin F Gainor; Leila Dardaei; Satoshi Yoda; Luc Friboulet; Ignaty Leshchiner; Ryohei Katayama; Ibiayi Dagogo-Jack; Shirish Gadgeel; Katherine Schultz; Manrose Singh; Emily Chin; Melissa Parks; Dana Lee; Richard H DiCecca; Elizabeth Lockerman; Tiffany Huynh; Jennifer Logan; Lauren L Ritterhouse; Long P Le; Ashok Muniappan; Subba Digumarthy; Colleen Channick; Colleen Keyes; Gad Getz; Dora Dias-Santagata; Rebecca S Heist; Jochen Lennerz; Lecia V Sequist; Cyril H Benes; A John Iafrate; Mari Mino-Kenudson; Jeffrey A Engelman; Alice T Shaw
Journal:  Cancer Discov       Date:  2016-07-18       Impact factor: 39.397

Review 2.  Role of liquid biopsy in oncogene-addicted non-small cell lung cancer.

Authors:  Matteo Canale; Luigi Pasini; Giuseppe Bronte; Angelo Delmonte; Paola Cravero; Lucio Crinò; Paola Ulivi
Journal:  Transl Lung Cancer Res       Date:  2019-11

Review 3.  Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.

Authors:  Ryohei Katayama; Christine M Lovly; Alice T Shaw
Journal:  Clin Cancer Res       Date:  2015-05-15       Impact factor: 12.531

4.  Editorial on the article entitled "brigatinib efficacy and safety in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer in a phase I/II trial".

Authors:  Ivana Sullivan; David Planchard
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

Review 5.  Targeting ALK: Precision Medicine Takes on Drug Resistance.

Authors:  Jessica J Lin; Gregory J Riely; Alice T Shaw
Journal:  Cancer Discov       Date:  2017-01-25       Impact factor: 39.397

Review 6.  Diagnosis and Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.

Authors:  Kathryn C Arbour; Gregory J Riely
Journal:  Hematol Oncol Clin North Am       Date:  2017-02       Impact factor: 3.722

Review 7.  Crizotinib resistance: implications for therapeutic strategies.

Authors:  I Dagogo-Jack; A T Shaw
Journal:  Ann Oncol       Date:  2016-09       Impact factor: 32.976

Review 8.  Routine clinical use of circulating tumor cells for diagnosis of mutations and chromosomal rearrangements in non-small cell lung cancer-ready for prime-time?

Authors:  Emma Pailler; Vincent Faugeroux; Marianne Oulhen; Cyril Catelain; Françoise Farace
Journal:  Transl Lung Cancer Res       Date:  2017-08

Review 9.  Treating ALK-positive non-small cell lung cancer.

Authors:  Dimitrios C Ziogas; Anna Tsiara; Georgios Tsironis; Maria Lykka; Michalis Liontos; Aristotelis Bamias; Meletios-Athanasios Dimopoulos
Journal:  Ann Transl Med       Date:  2018-04

Review 10.  Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer.

Authors:  Hideko Isozaki; Nagio Takigawa; Katsuyuki Kiura
Journal:  Cancers (Basel)       Date:  2015-04-30       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.